KR20180010198A - 종양 바이오마커 및 이의 용도 - Google Patents

종양 바이오마커 및 이의 용도 Download PDF

Info

Publication number
KR20180010198A
KR20180010198A KR1020177033956A KR20177033956A KR20180010198A KR 20180010198 A KR20180010198 A KR 20180010198A KR 1020177033956 A KR1020177033956 A KR 1020177033956A KR 20177033956 A KR20177033956 A KR 20177033956A KR 20180010198 A KR20180010198 A KR 20180010198A
Authority
KR
South Korea
Prior art keywords
methylpyridin
amine
naphthyridin
methyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020177033956A
Other languages
English (en)
Korean (ko)
Inventor
샤오리 친
송주 안
타오 황
Original Assignee
큐어제닉스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐어제닉스 코포레이션 filed Critical 큐어제닉스 코포레이션
Publication of KR20180010198A publication Critical patent/KR20180010198A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177033956A 2015-05-26 2016-05-26 종양 바이오마커 및 이의 용도 Abandoned KR20180010198A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562166305P 2015-05-26 2015-05-26
US62/166,305 2015-05-26
PCT/US2016/034245 WO2016191525A1 (en) 2015-05-26 2016-05-26 Tumor biomarkers and use thereof

Publications (1)

Publication Number Publication Date
KR20180010198A true KR20180010198A (ko) 2018-01-30

Family

ID=57394192

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177033956A Abandoned KR20180010198A (ko) 2015-05-26 2016-05-26 종양 바이오마커 및 이의 용도

Country Status (9)

Country Link
US (2) US20180112273A1 (https=)
EP (1) EP3302479A4 (https=)
JP (2) JP2018522062A (https=)
KR (1) KR20180010198A (https=)
CN (1) CN107708699A (https=)
AU (1) AU2016267142B2 (https=)
CA (1) CA2985813A1 (https=)
HK (1) HK1251171A1 (https=)
WO (1) WO2016191525A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142641A (zh) 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
RU2019101226A (ru) * 2016-06-22 2020-07-22 Новартис Аг Ингибиторы wnt для применения при лечении фиброза
WO2018117972A1 (en) * 2016-12-21 2018-06-28 Agency For Science, Technology And Research Kit for identifying malignancy, and uses thereof
CN107441045B (zh) 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CN108685923A (zh) * 2018-06-07 2018-10-23 广州源生医药科技有限公司 Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
CN102558173B (zh) * 2010-12-31 2015-05-20 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
KR102148303B1 (ko) * 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
EP2820151B1 (en) * 2012-02-28 2020-03-25 Novartis AG Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
CN105142641A (zh) * 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
CN105744954B (zh) * 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途

Also Published As

Publication number Publication date
JP2018522062A (ja) 2018-08-09
AU2016267142B2 (en) 2020-12-24
JP2021130694A (ja) 2021-09-09
CA2985813A1 (en) 2016-12-01
US20210054466A1 (en) 2021-02-25
EP3302479A4 (en) 2019-01-09
CN107708699A (zh) 2018-02-16
AU2016267142A1 (en) 2017-11-30
EP3302479A1 (en) 2018-04-11
HK1251171A1 (zh) 2019-01-25
US20180112273A1 (en) 2018-04-26
WO2016191525A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
US10660889B2 (en) Compounds for treatment of cancer
US20210054466A1 (en) Tumor biomarkers and use thereof
CN116406271B (zh) 双环类化合物
AU2016341445B2 (en) 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
WO2017161269A1 (en) Inhibitors of ret receptor tyrosine kinases
WO2025059366A1 (en) Ras inhibitors
CN110420327A (zh) 人ezh2抑制剂及其应用方法
CN104814970A (zh) 抑制egfr导致的癌症中细胞增殖的方法
CN109311888A (zh) 新的哌啶基衍生物，其制备方法和含有它们的药物组合物
WO2025101776A1 (en) Heterocycles and uses thereof
EP4567038A1 (en) Novel prmt5 inhibitor and use thereof
JP6585167B2 (ja) Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
JP2023513448A (ja) 複素環式化合物およびその使用
CN104105696B (zh) 5‑(吡啶‑2‑基‑氨基)‑吡嗪‑2‑腈化合物及其治疗用途
CN111565717A (zh) Myst家族组蛋白乙酰转移酶抑制剂
Du et al. Discovery and synthesis of a naturally derived protein kinase inhibitor that selectively inhibits distinct classes of serine/threonine kinases
KR20180011089A (ko) Ttk 억제제 화학요법을 위한 예후 바이오마커
KR20080090381A (ko) 테라뮤틴 조절물질
KR20210135521A (ko) 피롤로피라졸 유도체
CN108685923A (zh) Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用
CN119176820A (zh) 作为mat2a抑制剂的三环类化合物
CN120289454A (zh) Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000